On Nov 28, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $182 to $215.
Morgan Stanley analyst Matthew Harrison maintains with a buy rating, and maintains the target price at $200.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $203.
Oppenheimer analyst Andreas Argyrides maintains with a buy rating, and maintains the target price at $215.
Piper Sandler analyst Biren Amin maintains with a buy rating, and adjusts the target price from $200 to $182.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following the announcement of Sarepta's agreement with Arrowhead to license several clinical and preclinical programs, an analyst commented positively on the potential enhancement to the company's portfolio. It was noted that this agreement not only strengthens the company's pipeline but also provides potential for additional revenue streams beyond its existing DMD franchise. This strategic move is viewed as a crucial step in diversifying Sarepta's offerings, alleviating investor concerns about reliance on single-event gene therapies.
The collaboration with Arrowhead provides a diversified platform with a definitive long-term investment in chronic strategies for rare diseases, and further diversifies the therapeutic areas through clinical programs addressing muscle, central nervous system, and pulmonary indications. The strategic rationale for this deal complements Sarepta's expertise in rare genetic medicine, and the initiation of a share buyback indicates confidence in near-term revenue prospects.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
